País: Reino Unido
Idioma: inglés
Fuente: VMD (Veterinary Medicines Directorate)
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Pfizer Ltd
QI06AD04
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Expired
Revised: January 2011 AN: 01012/2010 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Feline 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION QUALITATIVE COMPOSITION Combined feline rhinotracheitis virus vaccine (live), freeze dried; feline calicivirus vaccine (live), freeze dried; and feline panleucopenia virus vaccine (live), freeze dried; and sterile diluent for veterinary use. QUANTITATIVE COMPOSITION 1. FREEZE-DRIED FRACTION: Active Ingredients Per 1ml dose Feline rhinotracheitis virus strain 2112 10 4.5 to 10 6.7 TCID 50 Feline calicivirus, strain 2113 10 5.5 to 10 7.7 TCID 50 Feline panleucopenia virus strain E 10 5.0 to 10 6.5 HAID 50 2. STERILE DILUENT Water for injection 1 ml Excipients: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection 4. CLINICAL PARTICULARS 5.1 TARGET SPECIES Cats 4.1 INDICATIONS FOR USE SPECIFYING THE TARGET SPECIES For the active immunisation of cats and kittens to reduce mortality and clinical signs caused by feline rhinotracheitis virus; to reduce clinical signs due to feline calicivirus; to prevent mortality and clinical signs and reduce the adverse effects on the immune system caused by feline panleucopenia virus infection. The onset of immunity is from two weeks after the second vaccination. The duration of immunity is at least one year for all three antigens. Page 1 of 5 Revised: January 2011 AN: 01012/2010 4.2 CONTRAINDICATIONS Do not vaccinate sick cats. 4.3 SPECIAL WARNINGS The effect of higher levels of maternally derived antibodies on the response to vaccination is not known. However, on the basis of field use, it Leer el documento completo